Skip to content

exisulind

DRUG10 trials

Sponsors

University of Utah, M.D. Anderson Cancer Center, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, Astellas Pharma Inc

Conditions

Breast NeoplasmsColorectal CancerLung CancerMetastases, NeoplasmNSCLCNon-Small Cell Lung CancerProstate CancerProstatic Neoplasms

Phase 1

Phase 2

Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
CompletedNCT00052845
Alliance for Clinical Trials in OncologyProstate Cancer
Start: 2002-11-30End: 2009-04-30Updated: 2016-07-01
Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer
CompletedNCT00041054
Alliance for Clinical Trials in OncologyLung Cancer
Start: 2002-06-30End: 2008-02-29Updated: 2016-12-07
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
CompletedNCT00041314
Eastern Cooperative Oncology GroupLung Cancer
Start: 2002-10-04End: 2007-06-15Updated: 2023-06-15
Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis
WithdrawnNCT00026468
University of UtahColorectal Cancer, Small Intestine Cancer
Start: 1999-07-31End: 1999-07-31Updated: 2013-07-24
Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer
CompletedNCT00078910
National Cancer Institute (NCI)Prostate Cancer
Start: 2003-08-31End: 2006-09-30Target: 130Updated: 2013-06-24
Exisulind Versus Placebo After Surgical Removal of the Prostate
CompletedNCT00166426
Mayo ClinicProstatic Neoplasms
Start: 2003-02-28End: 2008-05-31Target: 240Updated: 2009-11-16
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
CompletedNCT00283803
University of WashingtonProstate Cancer
Start: 2002-03-12End: 2011-10-31Updated: 2018-08-07

Phase 3